This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05686551
Recruitment Status : Recruiting
First Posted : January 17, 2023
Last Update Posted : March 29, 2024
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 28, 2026
Estimated Study Completion Date : April 1, 2027